|Bid||8.8800 x 800|
|Ask||8.8900 x 900|
|Day's Range||8.8100 - 9.3800|
|52 Week Range||4.1000 - 14.0000|
|Beta (3Y Monthly)||2.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.60|
‘It is much easier to take an existing patient and double their units,’ one sales manager wrote, referring to patients as ‘low hanging fruit.’
HENDERSON, NV / ACCESSWIRE / October 18, 2018 / With Canada getting set to make recreational marijuana legal on Wednesday, investors have been buying shares of CBD companies at an unbelievable pace. One company that has been flying and looks like it could continue its current pace Real Brands, Inc. (RLBD). RLBD successfully launched their CBD brand at the beginning of the year.
INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that its collaboration with the Center for Medicinal Cannabis Research (CMCR) at the University of California (UC) San Diego School of Medicine has added a third study. This additional study will evaluate the pharmacological effects of cannabidiol (CBD) oral solution from INSYS on anxiety associated with anorexia nervosa in adult patients.
Matt Donohue of Holland & Knight represents Insys Therapeutics but also sits on two committees appointed by the judge presiding over hundreds of lawsuits
INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the addition of Mark Nance to its senior management team as chief legal officer and general counsel. “As we continue to transform the company and advance the pipeline strategically and with agility, Mark’s addition will be critical to our executive leadership team,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics.
Insys Therapeutics (INSY) is a specialty pharmaceuticals company focused on developing cannabinoids and sprays. It reported EPS of -$0.37 on revenues of $23.47 million in the second quarter of 2018.
Insys Therapeutics’ (INSY) product pipeline includes cannabidiol oral solution and dronabinol inhalation. It also includes naloxone and epinephrine nasal sprays, buprenorphine and naloxone spray, and buprenorphine sublingual spray.
Biotechnology companies focused on marijuana-based products include GW Pharmaceuticals (GWPH), Cara Therapeutics (CARA), and Insys Therapeutics (INSY). In this series, we’ll look at these stocks and how they performed in the third quarter.
On Sept. 27, the United States Drug Enforcement Agency (DEA) made official a long-awaited decision on a cannabidiol (CBD)-based drug. GW Pharmaceuticals’ (NASDAQ:GWPH) drug Epidiolex was reclassified from Schedule 1 to Schedule 5.
INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that it has signed a definitive license agreement with Lunatus for commercialization of SUBSYS® (fentanyl sublingual spray) in eight countries in the Middle East. Today’s announcement confirms that the definitive agreement has been executed, making Dubai-based Lunatus the exclusive licensee and authorized agent for SUBSYS in the territory, which comprises Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia and the United Arab Emirates. Under the terms of this 10-year agreement, INSYS will supply SUBSYS to Lunatus, and Lunatus will obtain the regulatory approvals and commercialize SUBSYS in the territory.
HENDERSON, NV / ACCESSWIRE / September 28, 2018 / One stem cell play we like a lot is BioRestorative Therapies, Inc., (BRTX) a life sciences company focused on stem cell-based therapies. They recently ...
PHOENIX, Sept. 27, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that Saeed Motahari, ...
INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, recently completed a human proof-of-concept study of dronabinol inhalation using a novel and patented breath-actuated device licensed exclusively from U.K.-based Senzer Ltd. “This pharmacokinetic study provides evidence of our unique drug-device combination’s viability as a mechanism to deliver dronabinol into the distal lung for rapid systemic absorption,” said Steve Sherman, senior vice president of regulatory affairs for INSYS Therapeutics.
NEW YORK, NY / ACCESSWIRE / September 19, 2018 / U.S. markets closed up Tuesday on the strength of upbeat corporate earnings and strong economic data. On Tuesday, China announced tariffs of between 5 to ...
HENDERSON, NV / ACCESSWIRE / September 18, 2018 / A very interesting biotech firm DCTH (Delcath Systems, Inc.), has an intriguing treatment for liver cancer. The company has initiated a global Phase 3 ...
PHOENIX, Sept. 14, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that Saeed Motahari, ...
HENDERSON, NV/ ACCESSWIRE / September 14, 2018 / A fascinating biotech firm DCTH (Delcath Systems, Inc.), has a very intriguing treatment for liver cancer. The company has initiated a global Phase 3 clinical ...
Every investor in INSYS Therapeutics Inc (NASDAQ:INSY) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders oftenRead More...
Maryland authorities announced charges Thursday against an Arizona-based drugmaker that they say engaged in a nationwide scheme "characterized by extraordinary misconduct" to boost profits amid the coast-to-coast opioid epidemic. The office of Attorney General Brian Frosh filed charges against Insys Therapeutics alleging multiple violations of the state's consumer protection law. The pharmaceutical company makes a highly addictive opioid spray used to manage uncontrollable pain for adult cancer patients, but Frosh says Insys joined with local health care providers in a "calculated scheme" to target non-cancer patients, including those seeking relief from knee or back pain.
Maryland on Thursday charged Insys Therapeutics Inc with deceptively marketing a powerful opioid pain killer so that it was prescribed inappropriately beyond its intended use with cancer patients. Maryland Attorney General Brian Frosh announced that he had filed administrative charges against Arizona-based Insys, which he said provided thousands of dollars in inducements to doctors to promote prescribing its medication Subsys to their patients. Maryland alleged the company influenced doctors to prescribe the drug beyond its labeled use with inducements that included payments purported to be compensation for participating in educational events.
A settlement with the U.S. Department of Justice started August off on a good foot, but the month was capped off with a short squeeze.
HENDERSON,NV / ACCESSWIRE / September 4, 2018 / We have discovered an incredibly unique stem cell firm, BRTX (BioRestorative Therapies, Inc.). BRTX is on the cusp of receiving major attention from the ...
Investors need to pay close attention to INSYS Therapeutics (INSY) stock based on the movements in the options market lately.